Ipsen SA is showing no sign of slowing down on the dealmaking front and has bagged the ex-US licensing rights to Day One Biopharmaceuticals, LLC's recently approved brain cancer drug, Ojemda.
The French drugmaker is paying $111m upfront to get access internationally to Ojemda (tovorafenib), a type II RAF inhibitor which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?